Novo Nordisk announced that the marketing application for its new drug carelin peptide and simeglutide injection for long-term weight management has been accepted by the State Drug Administration. The drug is a fixed-dose compound preparation composed of the long-acting pancreatin receptor agonist carrelin peptide and the GLP-1 receptor agonist simeglutide, which is injected subcutaneously once a week. These two ingredients work together on pathways related to appetite and weight regulation through different and complementary mechanisms of action.

Novo Nordisk announced that the marketing application for its new drug carelin peptide and simeglutide injection for long-term weight management has been accepted by the State Drug Administration. The drug is a fixed-dose compound preparation composed of the long-acting pancreatin receptor agonist carrelin peptide and the GLP-1 receptor agonist simeglutide, which is injected subcutaneously once a week. These two ingredients work together on pathways related to appetite and weight regulation through different and complementary mechanisms of action.